PLIANT THERAPEUTICS, INC. Logo

PLIANT THERAPEUTICS, INC.

Developing novel integrin-based therapies for fibrosis and related diseases.

PLRX | US

Overview

Corporate Details

ISIN(s):
US7291391057
LEI:
Country:
United States of America
Address:
331 OYSTER POINT BOULEVARD, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The company leverages its proprietary discovery platform to create tissue-specific, integrin-based therapies. Its scientific approach centers on understanding and modulating the molecular drivers of fibrotic diseases, particularly TGF-β1 signaling, to develop potentially safer and more effective treatments. Pliant's development pipeline includes programs targeting a range of conditions, such as idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLIANT THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLIANT THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PLIANT THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America
950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea
041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea
260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea
014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America
KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan
4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan
4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia
KRKG
Krystal Biotech, Inc. Logo
Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.
United States of America
KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea
307750

Talk to a Data Expert

Have a question? We'll get back to you promptly.